BioXcel Therapeutics to Submit sNDA for At-Home Use of IGALMI in Agitation Treatment
核心洞察
BioXcel Therapeutics plans to submit a supplemental New Drug Application this month seeking FDA approval for at-home use of IGALMI in treating agitation associated with bipolar disorders or schizophrenia.
The company anticipates potential approval as early as 2026, which would address an unmet medical need as no FDA-approved options currently exist for at-home agitation treatment.
IGALMI is currently approved for supervised clinical use and contains dexmedetomidine, a selective alpha-2 adrenergic receptor agonist delivered via sublingual film.
BioXcel Therapeutics announced plans to submit a supplemental New Drug Application (sNDA) this month seeking FDA approval for at-home use of IGALMI® (dexmedetomidine) sublingual film in treating acute agitation associated with bipolar disorders or schizophrenia. The company believes approval could come as early as 2026, potentially filling a significant gap in treatment options for patients and caregivers.
"We are pleased with the progress towards submission of the sNDA and launch planning," said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. "Based on the accelerated submission timeline, we believe IGALMI could be approved for at-home use as early as 2026. We are now focused on launch planning and look forward to potentially introducing this important treatment option for agitation in the at-home setting, where patients and caregivers need it most and where there are no FDA-approved options currently available."
Current Approved Use and Mechanism
IGALMI is currently approved as a prescription medicine administered under healthcare provider supervision for acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The drug is placed under the tongue or behind the lower lip and contains dexmedetomidine, a selective alpha-2 adrenergic receptor agonist.
The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose, and its safety and effectiveness in children remains unknown.
Safety Profile and Monitoring Requirements
IGALMI carries several important safety considerations that require careful monitoring. The drug can cause decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, particularly in patients with low blood volume, diabetes, chronic high blood pressure, and older patients.
Heart rhythm changes, including QT interval prolongation, represent another significant concern. The drug should not be given to patients with abnormal heart rhythm, history of irregular heartbeat, slow heart rate, low potassium, low magnesium, or those taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death.
Additional safety considerations include sleepiness and drowsiness, requiring patients to avoid activities requiring mental alertness for at least 8 hours after administration. The drug also carries risks of withdrawal reactions, tolerance, and decreased response if used longer than 24 hours.
The most common side effects observed in clinical studies were sleepiness or drowsiness, prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.
Broader Development Pipeline
Beyond the current approved indication, BXCL501 (the investigational form of the drug) is under investigation for acute treatment of agitation associated with Alzheimer's dementia and for at-home treatment of agitation associated with bipolar I or II disorder or schizophrenia. The safety and efficacy for these investigational uses have not been established.
The compound has received significant regulatory recognition, including FDA Breakthrough Therapy designation for acute treatment of agitation associated with dementia and Fast Track designation for acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.
Company Profile and AI-Driven Approach
BioXcel Therapeutics positions itself as a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience. The company's drug re-innovation approach leverages existing approved drugs and clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications.
The company also operates OnkosXcel Therapeutics (搜索), a wholly owned subsidiary focused on developing medicines in immuno-oncology, expanding its therapeutic reach beyond neuroscience applications.